Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections

Keyphrases

• Cefepime 100%
• Complicated Intra-abdominal Infection (cIAI) 100%
• Community-acquired Infections 100%
• Metronidazole 100%
• Anti-infective Agents 100%
• Gram-negative Organisms 75%
• Antimicrobial 50%
• Healthcare-associated 50%
• Ileum 50%
• Community-acquired 50%
• Nosocomial Infection 50%
• Intra-abdominal Infection 50%
• Aerobic 50%
• Spectrum of Activity 50%
• Third-generation Cephalosporins 50%
• Quinolones 50%
• Pharmacist 25%
• Adult Patients 25%
• Immunosuppression 25%
• In Vitro Activity 25%
• Stomach 25%
• Moderate to Severe 25%
• Small Intestine 25%
• Medical Therapy 25%
• Abdominal 25%
• Physiologic 25%
• Acute Disease 25%
• Abscess Formation 25%
• Methicillin-resistant Staphylococcus Aureus 25%
• Scoring System 25%
• Colon 25%
• Resistance Pattern 25%
• Antibiotic Therapy 25%
• Ceftazidime 25%
• Pseudomonas Aeruginosa (P. aeruginosa) 25%
• Abdominal Surgery 25%
• Antimicrobial Therapy 25%
• Jejunum 25%
• Prospective Clinical Trial 25%
• Chronic Disease 25%
• Clindamycin 25%
• Pharmacy 25%
• Clinical Research 25%
• Evidence-based Recommendations 25%
• Computer-assisted 25%
• Surgical Infection 25%
• Intestinal Perforation 25%
• Culture Results 25%
• Microbiology 25%
• Timing of Initiation 25%
• Ertapenem 25%
• Healthcare-associated Infections 25%
• Piperacillin-tazobactam 25%
• Meropenem 25%
• Severe Infection 25%
• Empirical Therapy 25%
• Ciprofloxacin 25%
• Peritonitis 25%
• Duodenum 25%
• Infectious Diseases Society of America 25%
• Multidrug Regimen 25%
• Reduced Mortality 25%
• Ampicillin-sulbactam 25%
• Anaerobic Organism 25%
• Imipenem-cilastatin 25%
• Enterococcus Species 25%
• Susceptibility Testing 25%
• Narrow Spectrum 25%
• Ceftriaxone 25%
• Cefazolin 25%
• Candida Species 25%
• Moderate Severity 25%
• Microbiologist 25%
• Nosocomial Isolates 25%
• Duration of Therapy 25%
• Cefoxitin 25%
• Community Health 25%
• Enterobacter Species 25%
• Infectious Disease Pharmacist 25%
• Interactive Session 25%
• Anaerobic Microorganisms 25%
• Culture Duration 25%
• Susceptibility Profile 25%
• Bacteroides Fragilis Group 25%
• Design Errors 25%
• Multiple Agents 25%
• Preperitoneal Space 25%
• Hollow Viscus 25%
• Ticarcillin-clavulanate 25%
• Cefotetan 25%
• Aerobic Gram-negative Bacilli 25%
• Drug Utilization Study 25%
• Assisted Care 25%
• Proteus Species 25%

Medicine and Dentistry

• Infection 100%
• Antiinfective Agent 100%
• Abdominal Infection 100%
• Gram-Negative Bacteria 40%
• Community Acquired Infection 40%
• Metronidazole 40%
• Health Care 20%
• Hospital Infection 20%
• Quinolone Derivative 20%
• Ileum 20%
• Health Care Cost 10%
• In Vitro 10%
• Clinical Trial 10%
• Immunosuppressive Treatment 10%
• Clinical Research 10%
• Combination Therapy 10%
• Nurse 10%
• Acute Disease 10%
• Surgical Infection 10%
• Abscess 10%
• Scoring System 10%
• Colon 10%
• Antibiotic Therapy 10%
• Pseudomonas aeruginosa 10%
• Ceftazidime 10%
• Treatment Duration 10%
• Jejunum 10%
• Chronic Disease 10%
• Clindamycin 10%
• Antimicrobial Therapy 10%
• Methicillin Resistant Staphylococcus Aureus 10%
• Gastrointestinal Perforation 10%
• Ertapenem 10%
• Meropenem 10%
• Piperacillin/Tazobactam 10%
• Digestive System Surgery 10%
• Healthcare Associated Infection 10%
• Combination Drug 10%
• Infectious Disease 10%
• Cephalosporin Derivative 10%
• Peritonitis 10%
• Duodenum 10%
• Enterococcus 10%
• Ciprofloxacin 10%
• Ampicillin/Sulbactam 10%
• Viscera 10%
• Cefepime 10%
• Enterobacter 10%
• Bacteroides fragilis 10%
• Empirical Treatment 10%
• Cefazolin 10%
• Cefuroxime 10%
• Ceftriaxone 10%
• Cefoxitin 10%
• Imipenem/Cilastatin 10%
• Clavulanic Acid 10%
• Ticarcillin 10%
• Cefotaxime 10%
• Ceftizoxime 10%
• Cefotetan 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Antiinfective Agent 100%
• Abdominal Infection 100%
• Gram Negative Bacterium 40%
• Community Acquired Infection 40%
• Metronidazole 40%
• Hospital Infection 20%
• Quinolone Derivative 20%
• Ileum 20%
• Combination Therapy 10%
• Clinical Trial 10%
• Acute Disease 10%
• Surgical Infection 10%
• Pseudomonas aeruginosa 10%
• Ceftazidime 10%
• Abscess 10%
• Clindamycin 10%
• Chronic Disease 10%
• Enterococcus 10%
• Antimicrobial Therapy 10%
• Antibiotic Therapy 10%
• Clinical Research 10%
• Methicillin-Resistant Staphylococcus Aureus 10%
• Digestive System Perforation 10%
• Anaerobic Bacterium 10%
• Ertapenem 10%
• Healthcare Associated Infection 10%
• Candida 10%
• Combination Drug 10%
• Piperacillin Plus Tazobactam 10%
• Cephalosporin Derivative 10%
• Peritonitis 10%
• Cilastatin 10%
• Imipenem 10%
• Jejunum 10%
• Cefazolin 10%
• Ciprofloxacin 10%
• Drug Utilization 10%
• Cefepime 10%
• Meropenem 10%
• Clavulanic Acid 10%
• Ceftriaxone 10%
• Bacteroides fragilis 10%
• Cefuroxime 10%
• Enterobacter 10%
• Cefoxitin 10%
• Cefotaxime 10%
• Ticarcillin 10%
• Cefotetan 10%
• Sultamicillin 10%
• Ceftizoxime 10%
• Diseases 10%